3 documents found, page 1 of 1
Biologic disease-modifying antirheumatic drugs survival in late-onset axial spo...
Silva, Susana P.; Monteiro, Beatriz; Oliveira, Cláudia Pinto; Costa, Roberto Pereira da; Matos, Carolina Ochôa; Lopes, Mariana DizObjectives Although axial spondyloarthritis (axSpA) typically begins before age 45, late-onset axSpA (lo-axSpA) has been widely recognized. While existing literature describes this subgroup, data on therapeutic approaches remain limited. Therefore, we aimed to evaluate the efficacy and safety of biologic DMARDs in patients with lo-axSpA.Methods We conducted a retrospective, multicentre, national cohort study us...
Jaccoud’s arthropathy in osteogenesis imperfecta
Martins, Frederico Rajão; Rocha, Margarida Lucas; Chícharo, Ana Teodósio; Teixeira, Vítor SilvestreType I osteogenesis imperfecta is a genetic disease associated with mutations in the pro-alpha1 chains of type 1 collagen encoder gene COL1A1. It has an autosomal dominant pattern of inheritance, and leads to reduction in the amount of structurally normal collagen and subsequently, disorders of the extracellular membrane of skin, tendons and bone.
Prevalence and clinical characteristics of late Onset Axial Spondyloarthritis: ...
Rocha, Margarida Lucas; Torres, R.; Ramiro, S.; Castro, A. M.; Neves, A.; Martins, A.; Chícharo, A. T.; Mendes, B.; Matos, C. O.; Soares, C.Axial spondyloarthritis (axSpA) typically starts before the fourth decade oflife. Consistent with that, the Assessment of SpondyloArthritis international Society (ASAS)classification criteria for axSpA should be applied only in patients with chronic back pain startingbefore 45 years of age. It has, however, been suggested that axSpA can sometimes start later in lifewith a distinctive phenotype, the so-called ‘l...